|Day Low/High||20.24 / 21.42|
|52 Wk Low/High||20.12 / 58.72|
ACAD was downgraded Monday by TheStreet's Quant Ratings service.
A long repair process will be needed in the months ahead. Let's check the charts.
The market's mood seems to be changing almost daily; he's an approach for how to trade it regardless of how it's feeling on any particular day.
These names are displaying both technical and quantitative deterioration.
Various hard-charging mega-cap stocks seem overdue for a significant pause, while a drop in Acadia Pharmaceuticals sets up an options play.
Eagle Pharmaceuticals, Biohaven Pharmaceuticals and Acadia Pharmaceuticals are names to consider on a 10% move down in equities.
Acadia Pharmaceuticals and HD Supply each have seen significant insider purchases of late.
There are multiple reasons why these stocks often decline after their drugs receive the blessing of regulators.
There isn't much choice but to buy strength.
The aging population is creating a massive tailwind for companies that provide cutting-edge health care.
We review Acadia Pharmaceuticals, The Medicines Company, and Flexion Therapeutics.
Intra-Cellular Therapies and Acadia Pharmaceuticals are worth investors' attention.
Quick takes on fourth-quarter results from these 3 biotech names.
These names are showing technical characteristics of either bullish or bearish reversal patterns.
In 2017, McCamant's model portfolio rose 65%, while his trader's portfolio rose 98%.
Great being here on Daily Diary today. Nice to see a huge rally for once standing in for Dougie as well. Lots of good conversation as the markets close near their highs for the day. Some big moves in the small biotech names that are near and dear to...
The April Jobs report showed that 164,000 jobs were created last month. This is nearly 30,000 jobs less than the consensus. Unemployment rates tumbles to 3.9%, the first time under the 4% level in almost two decades. A rash of biotech news hitting t...
I continue to keep a 'shopping list' at the ready for the next dip in the market.
Recently I have noticed some of Wall Street's younger analysts engaging in "multiple creep." They seem to be treating a 12 EBITD (cash flow) multiple like a 12 PE (price to earnings) ratio. Whoops! No problem, for example, paying 25x EPS for ....Unt...
The biotech sector has seen a big rally, but there are still opportunities.
Readers have asked about Acadia Pharmaceuticals and Dynavax Technologies, so we answer.
"If you work for a living, why do you kill yourself working?" -- Tuco, The Ugly: "The Good, the Bad and the Ugly" There was plenty of sector rotation today (but little overall movement), so let's move to the abbreviated Monarch Notes form of "Takeaw...
The Plymouth Meeting, Pa.-based firm said a Phase 1 study of Zika vaccine GLS-5700 'induced high levels of binding antibodies in 100% of participants.'
Prospects for acquisition activity in the sector are improving.
ACAD looks strong enough for a rally at least to the upper $30s.